Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours
The primary objective of the study was to identify the maximum tolerated dose and to evaluate safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992.
Neoplasms
DRUG: BIBW 2992
Maximum tolerated dose (MTD) of BIBW 2992, up to 24 weeks|Incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTC version 3) associated with increasing doses of BIBW 2992, up to 28 weeks
Area under the plasma concentration-time curve (AUC) for several time points, up to 648 hours after first drug administration, pre-dose on day 15 and 28|Percentage of AUC0-∞ that is obtained by extrapolation (%AUCtz-∞), up to 648 hours after first drug administration, pre-dose on day 15 and 28|predose plasma concentration, predose on days 8, 15, 22 and 27|Plasma concentration, 24 hours after drug administration on the first (C24,1) and the Day 27 dose (C24,27)|Maximum measured plasma concentration (Cmax) for several time points, up to 648 hours after first drug administration, pre-dose on day 15 and 28|Time from dosing to the maximum plasma concentration (tmax) for several time points, up to 648 hours after first drug administration, pre-dose on day 15 and 28|terminal half-life (t1/2(ss)), up to 648 hours after first drug administration, pre-dose on day 15 and 28|mean residence time after oral administration (MRTpo(ss)), up to 648 hours after first drug administration, pre-dose on day 15 and 28|apparent clearance (CL/F(ss)), up to 648 hours after first drug administration, pre-dose on day 15 and 28|apparent volume of distribution during the terminal phase (Vz/F(ss)), up to 648 hours after first drug administration, pre-dose on day 15 and 28|Accumulation ratio between Day 1 and Day 27 with respect to Cmax (RA1) and AUC (RA2), up to 648 hours after first drug administration, pre-dose on day 15 and 28|Modulation of biomarker (EGFR, p-EGFR, p-MAPK, p-Akt, Ki 67, p-27KIP1) in skin biopsies, Baseline and day 28 of the first treatment period|Modulation of biomarker (EGFR, p-EGFR, HER2 (Class I Tyrosine Kinase Receptor), p-MAPK (mitogen-activated protein kinase), p-Akt, Ki 67, p-27KIP1) in tumour biopsies in six or more patients treated at the MTD, Baseline and day 28 of the first treatment period|Objective tumour response, up to 25 weeks|Correlation of EGFR, HER2, estrogen receptor (ER) and progesterone receptor (PrR) immunohistochemical status as based on tumour biopsies, or excisions obtained prior to this study, with objective tumour responses, up to 25 weeks
The primary objective of the study was to identify the maximum tolerated dose and to evaluate safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992.